CYPH · XBRL financial data

Cypherpunk Technologies financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CYPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,500	1,500	—	—	—	—
Research and development	20,423	32,160	44,965	73,234	57,211	25,670
General and administrative	9,616	10,766	11,798	13,807	12,846	10,870
Total operating expenses	30,039	42,926	56,763	87,041	70,057	41,067
Operating income (loss)	(28,539)	(41,426)	(56,763)	(87,041)	(70,057)	(41,067)
Interest expense	39	41	54	—	—	24
Income tax expense (benefit)	(2)	(24)	147	—	585	5,255
Net income (loss)	(27,514)	(40,587)	(54,596)	(81,414)	(67,555)	4,822
Earnings per share, basic‡ USD per share	(6.30)	(4.70)	(4.80)	(3.98)	(1.81)	0.07
Earnings per share, diluted‡ USD per share	(6.30)	(4.70)	(4.80)	(3.98)	(1.81)	0.07
Weighted average shares, basic‡ thousands of shares	5,933	8,583	11,324	20,445	37,551	66,140
Weighted average shares, diluted‡ thousands of shares	5,933	8,583	11,324	20,445	37,551	70,672

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2023); filings made before it reported them unadjusted.

Fiscal years (CYPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	52,071	114,916	65,500	70,643	47,249	14,035
Prepaid and other current assets	130	769	351	183	86	40
Total current assets	52,274	116,874	67,950	71,597	48,039	162,081
Property and equipment, net	65	36	20	5	0	—
Right-of-use asset	528	459	669	257	262	38
Total assets	54,371	117,911	70,353	72,825	49,124	163,182
Accounts payable	2,717	4,189	5,657	6,465	4,743	1,981
Accrued liabilities	2,747	5,366	5,152	5,957	8,536	2,067
Total current liabilities	7,372	9,987	11,225	12,684	14,076	4,558
Lease liability, non-current	144	37	262	—	—	—
Total liabilities	7,720	10,024	11,487	12,684	14,076	9,676
Accumulated deficit	(222,985)	(263,572)	(318,168)	(399,582)	(467,371)	(462,549)
Total stockholders' equity	46,651	107,887	58,866	60,141	35,048	153,506
Total liabilities and equity	54,371	117,911	70,353	72,825	49,124	163,182
Common shares outstanding (cover page)‡ thousands of shares	5,966	8,832	11,875	25,600	41,258	89,980

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2023); filings made before it reported them unadjusted.

Fiscal years (CYPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(27,514)	(40,587)	(54,596)	(81,414)	(67,555)	4,822
Stock-based compensation	2,572	3,686	5,180	5,128	5,504	4,899
Net cash from operating activities	(25,957)	(35,157)	(49,044)	(43,753)	(60,299)	(43,902)
Net cash from investing activities	25	—	—	48,969	—	(97,000)
Net cash from financing activities	73,997	98,035	(210)	(30)	37,184	107,649
Net change in cash	48,180	62,845	(49,416)	5,143	(23,394)	(33,214)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cypherpunk Technologies	7,624	not reported	(2,692)*	107.8M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Citius Pharmaceuticals	17,008	1,494	(8,678)*	27.5M	2.0 quarters	Q3 FY26 10-QJun 30, 2026
Synergy CHC	292	5,493	(2,045)	14.9M	0.1 quarters	Q1 FY26 10-QMar 31, 2026
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palisade Bio	125,172	500	(7,603)*	174.3M	16.5 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.